Logotype for Centessa Pharmaceuticals plc

Centessa Pharmaceuticals (CNTA) investor relations material

Centessa Pharmaceuticals Morgan Stanley 23rd Annual Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Centessa Pharmaceuticals plc
Morgan Stanley 23rd Annual Global Healthcare Conference summary9 Sep, 2025

Key program updates and scientific insights

  • Significant progress in the orexin agonist program, with ORX-750 and ORX-142 advancing in clinical development.

  • Orexin agonists are positioned as transformative for narcolepsy and other hypersomnias, targeting the underlying cause rather than symptoms.

  • ORX-750 features a flexible, once-daily dosing profile, with proprietary design based on crystal structure insights.

  • Phase 2a CRYSTAL-1 study uses adaptive, real-time dose optimization across NT1, NT2, and IH, aiming for best-in-class efficacy and tolerability.

  • Data from ORX-142, a more potent molecule, is expected this year, with potential for broader neurodegenerative and neuropsychiatric indications.

Clinical data and competitive landscape

  • Phase 1 data for ORX-750 showed strong maintenance of wakefulness and favorable safety, with minimal difference from placebo.

  • Higher doses are needed for NT2 and IH due to intact orexin systems, while NT1 requires lower doses.

  • Competitor data at World Sleep Congress reinforced confidence in the program and highlighted commercial focus.

  • Aim to launch one molecule across all three indications, simplifying treatment for physicians and patients.

  • Enthusiasm among physicians is high, with expectations that orexin agonists could redefine standards of care.

Market opportunity and financial position

  • Rare hypersomnias represent a market opportunity exceeding $15 billion, with NT1 alone estimated at $6–7 billion.

  • Cash position of $400 million as of June 30, providing runway into mid-2027.

  • Intellectual property strategy and medicinal chemistry expertise provide a competitive moat in the orexin agonist space.

  • AI is leveraged in clinical operations, but human relationships remain central to execution.

  • Regulatory and tariff risks are considered manageable, with contingencies in place.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Centessa Pharmaceuticals earnings date

Logotype for Centessa Pharmaceuticals plc
Q3 202511 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Centessa Pharmaceuticals earnings date

Logotype for Centessa Pharmaceuticals plc
Q3 202511 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company dedicated to discovering, developing, and delivering transformative medicines. Established in 2020, the company focuses on developing a wide range of innovative treatments across various therapeutic areas, including rare diseases and immuno-oncology. Centessa Pharmaceuticals is headquartered in Altrincham, United Kingdom, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage